The Journal of Clinical Endocrinology & Metabolism · 1977 · 20 citations · 0 references
MedicineEndocrinologyPharmacologyClinical PharmacologyDrug MetabolismSteroid BiochemistryAdrenal DisordersAdrenal EndocrinologyAdrenal Steroid HormonesAdrenal SteroidogenesisDrug DispositionSteroid PharmacologyAdrenal Androgen ProductionAdrenal Steroid PharmacologyAdrenal Steroidogenic DisordersDisorders Of Adrenal SteroidogenesisPaper ChromatographyPlasma Steroid ProfilingSpironolactone Therapy
The increase of plasma deoxycorticosterone (DOC) levels after administration of spironolactone is a real effect and not due to cross-interference of the drug or its metabolites with the DOC-assay. This is proved by in vitro and in vivo results. Of all the metabolites only canrenone interferes to some extent with DOC after liquid-liquid-extraction and paper chromatography. The antiserum, however, is so highly specific, that the final cross-interference of the total procedure amounts to less than 2% of the DOC plasma levels. Moreover, in patients with Addison's disease only a very small increase of DOC plasma levels can be observed after administration of spironolactone in contrast to normal subjects.